YTYoe Kie Onno Teng

Yoe Kie Onno Teng

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yoe Kie Onno Teng has a total of 604 co-authors. Here are the top co-authors by number of shared publications:

  • Ton Johannes Rabelink

    Department of Internal Medicine, Division of Nephrology, Einthoven Laboratory of Vascular and Regenerative Medicine, Leiden University Medical Center, Leiden, the Netherlands

    20 shared publications
  • Cees van Kooten

    Department of Nephrology, LuVaCs Center of Expertise for Lupus, Vasculitis and Complement-associated systemic diseases, Leiden University Medical Center, Leiden, The Netherlands

    15 shared publications
  • Kathryn I. Stevens

    Glasgow Renal and Transplant Unit, Queen Elizabeth University Hospital , Glasgow

    15 shared publications
  • Safak Mirioglu

    Division of Nephrology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University , Istanbul

    15 shared publications
  • Andreas Kronbichler

    Department of Health, Medicine and Caring Sciences, Linköping University , Linköping

    14 shared publications
  • Eleni Frangou

    Department of Nephrology, Limassol General Hospital, State Health Service Organization , Limassol

    14 shared publications

Latest Publications

  • Open Access

    CD19-CAR T cells reset the EBV + autoreactive B cell repertoire in autoimmune disease

    by Ya’EL Courtney, Mahesh Pandit, Laura S. van Dam, Shady Younis, Sajede Rasouli, Mengrui Zhang, Yashaar Chaichian, Shima Parsafar, Tobias V. Lanz, Eline J. Arends, et al.

    Epstein-Barr virus (EBV) reprograms autoreactive B cells into activated antigen-presenting cells that drive pathogenic T- and B-cell responses in autoimmune disease. 1–4 Whether eliminating these cells contributes to durable remission after CD19 chimeric antigen receptor (CAR) T-cell therapy 5–7 is unknown. Here, using EBV B-cell sequencing (EBV-seq) 3 , we profiled EBV + B cells from patients treated with CD19-CAR T cells (systemic lupus erythematosus, n=6; inflammatory myopathy, n=3; systemic sclerosis, n=3) or rituximab (n=15) and recombinantly expressed their antibodies to define antigen specificity. At baseline, EBV + B cells were enriched relative to healthy donors, class-switched and hypermutated, expressed the latency III program with heightened antigen-presentation signatures, and encoded autoantibodies. CAR T cells, but not rituximab, depleted EBV + B cells and shifted the reconstituted repertoire towards IgM + , minimally mutated, largely non-autoreactive cells, consistent with infection of newly generated B cells. After rituximab, EBV + B cells retained a class-switched, hypermutated and autoreactive with an activated antigen-presenting phenotype. Sustained drug-free remission occurred in 8/12 CAR T-cell-treated versus 0/15 rituximab-treated patients. In vitro , EBV + B cells resisted anti-CD20 and anti-CD19 antibodies but were killed by CAR T cells and a CD19 T-cell engager. Our findings suggest resetting the EBV + autoreactive B-cell repertoire contributes to sustained drug-free remission.

  • Avacopan across borders: regulatory divergence and treatment dilemmas for ANCA-associated vasculitis

    by Y K Onno Teng, Julie Power, Kasia Wawrzycka-Adamczyk, European Reference Network For Rare Immunological Diseases (Ern Rita) Autoimmune Vasculitis Taskforce

  • Open Access

    Unmet needs in the management of adult patients with lupus nephritis

    by Seyda Gul Ozcan, Annette Bruchfeld, Fernando Caravaca-Fontan, Sarah M Moran, Stefanie Steiger, Kate I Stevens, Y K Onno Teng, Eleni Frangou, Andreas Kronbichler, Luis F Quintana, et al.

    Lupus nephritis is a major cause of morbidity and long-term kidney damage in patients with systemic lupus erythematosus. Despite therapeutic advances, complete remission rates remain modest, and progress to kidney failure still occurs in a substantial proportion of patients. Contemporary management has shifted toward early initiation of ‘triple therapy’, yet patients continue to suffer from the adverse effects of prolonged glucocorticoid exposure. Challenges persist, including treatment duration, safe tapering, and the high rates of flare following immunosuppression withdrawal, underscoring the potential role of repeat kidney biopsy in guiding decisions. Poor adherence is very common and a significant impediment in daily practice and often leads to the incorrect classification of patients as having ‘refractory disease’. Furthermore, conventional biomarkers are not ideal for flare prediction. Emerging therapies offer promising efficacy but remain inaccessible for many patients due to high costs and different reimbursement policies. Comprehensive management further requires attention to pregnancy planning, infection prophylaxis, care of chronic kidney disease, and long-term complications such as malignancy and osteoporosis. The goal should be to preserve kidney function, minimize cumulative toxicity, and restore quality of life to all patients, regardless of geography or economic status. This article provides a perspective of the Immunonephrology Working Group of the European Renal Association and discusses the key unmet needs in the management of lupus nephritis.

  • Open Access

    Ten tips for the diagnosis and management of nephrotic syndrome

    by Ilay Berke, Annette Bruchfeld, Eleni Frangou, Sarah M Moran, Luis F Quintana, Kate I Stevens, Y K Onno Teng, Stefanie Steiger, Andreas Kronbichler, Safak Mirioglu

    Nephrotic syndrome (NS) encompasses a heterogeneous group of glomerular diseases characterized by heavy proteinuria, hypoalbuminemia, edema, and multiple systemic complications. Despite substantial advances in diagnostic techniques and targeted therapies, the management of NS remains challenging in clinical practice. In addition to complex treatment decisions, clinicians must address diagnostic uncertainty, recognize secondary causes, and prevent potentially serious complications including thrombosis, infections, cardiovascular disease, and progressive kidney dysfunction. Adverse outcomes in NS frequently arise not only from inappropriate management but also from overlooked steps in diagnosis, monitoring, and long-term care. Here, we present 10 practical tips to improve clinical decision-making in the diagnosis and management of NS. Key positive strategies include appropriate use of kidney biopsy and modern immunopathologic techniques, integration of immunologic biomarkers such as anti-phospholipase A2 receptor antibodies in the evaluation of membranous nephropathy, systematic exclusion of secondary causes, and comprehensive supportive care including blood pressure control, antiproteinuric therapy, and thrombosis prophylaxis in high-risk patients. In addition, evidence-based use of immunosuppressive therapies (IST) tailored to specific disease entities is emphasized. Equally important are commonly overlooked pitfalls that may compromise outcomes, including delayed genetic testing in steroid-resistant disease, prolonged ineffective immunosuppression, inadequate post-transplant surveillance for recurrence, under-recognition of cardiovascular risk, and failure to prevent complications associated with IST. Highlighting these practical considerations may help increase awareness of common pitfalls and support more attentive clinical management of patients with NS.

  • Open Access

    Management of recurrent C3 glomerulopathy after kidney transplantation

    by Hernando Trujillo, Teresa Cavero, Sarah M Moran, Safak Mirioglu, Annette Bruchfeld, Stefanie Steiger, Kate I Stevens, Eleni Frangou, Luis F Quintana, Andreas Kronbichler, et al.

    C3 glomerulopathy (C3G) is an ultra-rare, complement-mediated glomerular disease characterized by dysregulation of the alternative complement pathway and a high propensity for recurrence after kidney transplantation. Although kidney transplantation remains the optimal treatment for patients reaching kidney failure, post-transplant recurrence continues to be a major cause of graft dysfunction and loss. Over the past decade, improved histopathologic recognition and the increasing adoption of protocol biopsies have revealed that C3G frequently recurs early after transplantation, often in a subclinical form. At present, no validated clinical, genetic, or functional biomarkers reliably predict recurrence, and preventive strategies remain unproven. Consequently, from our standpoint, management of recurrent C3G requires a pragmatic, surveillance-driven approach rather than prophylactic intervention. In this review, we provide a practical framework for managing recurrent C3G after kidney transplantation, from transplant candidacy and pretransplant evaluation to post-transplant monitoring and therapeutic decision-making. We discuss the role of protocol biopsies, the limitations of conventional immunosuppression, and the emerging place of proximal complement inhibitors. Finally, we highlight several unmet needs that continue to limit optimal care, including persistent uncertainty about therapeutic goals, management of subclinical histologic recurrence, and interpretation of treatment response. This review reflects a transplant-centered clinical perspective aimed at supporting nephrologists in real-world decision-making.

  • Disease modification in lupus nephritis: towards a pathophysiology-based treatment paradigm

    by Mieke van Schaik, Cees van Kooten, Laurent Arnaud, Annette Bruchfeld, Fernando Caravaca-Fontán, Gema M. Fernandez Juarez, Jürgen Floege, Ana Malvar, Safak Mirioglu, Sarah Moran, et al.


  • Open Access

    Pivotal Clinical Trials in C3 Glomerulopathy: answers and remaining uncertainties

    by Fernando Caravaca-Fontan, Annette Bruchfeld, Sarah M Moran, Stefanie Steiger, Kate I Stevens, Y K Onno Teng, Eleni Frangou, Safak Mirioglu, Luis F Quintana, Andreas Kronbichler

    Complement 3 glomerulopathy (C3G) and primary immune complex–mediated membranoproliferative glomerulonephritis (IC-MPGN) are ultra-rare glomerular diseases driven by dysregulation of the complement system, most commonly involving the alternative pathway. Recent advances in the understanding of disease pathogenesis have enabled the development of targeted complement therapies. The publication of pivotal phase 3 trials evaluating proximal complement inhibitors –iptacopan, a selective factor B inhibitor, and pegcetacoplan, a C3 inhibitor– marks a turning point in the management of C3G and IC-MPGN. Both agents demonstrated clinically meaningful reductions in proteinuria and stabilization of kidney function, establishing proof of efficacy. Despite these advances, important uncertainties remain. Key unresolved issues include optimal patient selection, timing and duration of therapy, treatment sequencing, monitoring strategies, and long-term kidney outcomes. Conventional immunosuppressive approaches provide inconsistent benefit and do not directly address complement dysregulation, while validated biomarkers to guide complement blockade are lacking. Additional challenges relate to treatment discontinuation, management of special populations, and health-system implementation. This review critically appraises the evidence from recent pivotal trials, highlighting both their transformative impact and the questions they raise. We emphasize the need for long-term outcome studies, precision-based therapeutic strategies, and pragmatic real-world data. Ultimately, the challenge ahead is not whether complement inhibition is effective but how best to deploy these therapies to maximize durable benefit, minimize risk, and ensure equitable access.

  • Open Access

    Cost-effectiveness of the sFlt-1/PlGF ratio and telemonitoring in managing suspected pre-eclampsia: protocol for the PREPARE II randomised controlled trial

    by M Wind, A Peters, M E van Den Akker-Van Marle, K Vanden Auweele, L van Bodegom-Vos, F Boekhorst, C M Cobbaert, W Hermes, M E Van Hoorn, L Van Den Haak, et al.

    Introduction: The soluble FMS-like tyrosine kinase-1 and placental growth factor (sFlt-1/PlGF) ratio has demonstrated impressive predictive test characteristics in women with suspected pre-eclampsia. However, it remains a matter of debate whether the introduction of this novel test can indeed translate to a reduction in pre-eclampsia-related hospital admissions, outpatient visits and can consequently lower overall healthcare costs. The PREPARE II study aims to investigate whether the sFlt-1/PlGF ratio, along with digital self-monitoring, can reduce pre-eclampsia-related healthcare utilisation in the first week following the test for women with suspected pre-eclampsia. Methods and analysis: This is a randomised controlled trial across six centres which includes women (≥16 years old) between 20 and 37 weeks of gestation with suspected pre-eclampsia due to one or more identified symptoms. For power calculation, we assumed that the sFlt-1/PlGF ratio including a telemonitoring strategy leads to a de-escalation of care by cumulatively reducing the frequency of pre-eclampsia-related hospital admissions and/or outpatient visits in the first week from 50% in the control group to 35% in the intervention group. Considering a loss to follow-up of 5%, a sample size of approximately 470 women is required with 235 women per arm (α=5%; power=90%). The intervention is an algorithm based on the urine protein/creatinine ratio (PCr)+sFlt-1/PlGF ratio, along with a telemonitoring strategy. The algorithm incorporates a PCr cut-off of 30 (mg/mmol) and a sFlt-1/PlGF ratio cut-off of 38 for risk classification. Subsequent clinical follow-up recommendations are stratified based on this classification: low risk entails no additional follow-up, returning to routine antenatal care; intermediate risk includes telemonitoring; high risk necessitates immediate admission. The primary outcome is the occurrence of pre-eclampsia-related healthcare utilisation in the first week after testing. Secondary outcomes are maternal/perinatal adverse events, total healthcare usage, pre-eclampsia diagnosis, quality of life and productivity losses. A cost-effectiveness analysis from a societal perspective will be performed. Ethics and dissemination: Ethical approval was obtained from the Medical Ethics Committee of Leiden University Medical Centre (METC LDD) on 21 July 2025 (reference NL-009295). The results will be disseminated through peer-reviewed publications and presentations at international conferences. Trial registration: NL88527.058.24.

  • Open Access

    Comparative analysis of lupus nephritis guidelines: ACR 2025, EULAR 2025, and KDIGO 2024

    by Marc Xipell, Maria Iraola, Safak Mirioglu, Sarah M Moran, Stefanie Steiger, Kate I Stevens, Y K Onno Teng, Eleni Frangou, Annette Bruchfeld, Luis F Quintana, et al.

    Lupus nephritis (LN) is a major driver of morbidity and kidney failure in systemic lupus erythematosus, and its management has grown substantially more complex with the emergence of targeted therapies. Between 2024 and 2025, the American College of Rheumatology, the European Alliance of Associations for Rheumatology, and Kidney Disease: Improving Global Outcomes each released updated recommendations grounded in a largely shared evidence base but differing in scope, clinical profiling, and operational emphasis. This review compares the three frameworks, highlighting key areas of convergence and divergence relevant to contemporary clinical practice. The main themes include the shift toward early combination regimens targeting complementary immune pathways, driven by the emergence of targeted therapies such as belimumab, voclosporin, and obinutuzumab; the incorporation of clinical profiling to guide therapy selection and monitoring; strategies aimed at rapid glucocorticoid minimization; and the growing recognition of renoprotective therapy as a central pillar of LN care within a chronic kidney disease management strategy.